FMP

FMP

Enter

ALLK - Allakos Inc.

Financial Summary of Allakos Inc.(ALLK), Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomo

photo-url-https://financialmodelingprep.com/image-stock/ALLK.png

Allakos Inc.

ALLK

NASDAQ

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

1.08 USD

-0.03 (-2.78%)

About

ceo

Dr. Robert Alexander Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.allakos.com

exchange

NASDAQ

Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; ...

CIK

0001564824

ISIN

US01671P1003

CUSIP

01671P100

Address

975 Island Drive

Phone

650 597 5002

Country

US

Employee

131

IPO Date

Jul 19, 2018

Summary

CIK

0001564824

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

01671P100

ISIN

US01671P1003

Country

US

Price

1.08

Beta

0.81

Volume Avg.

1.45M

Market Cap

94.9M

Shares

-

52-Week

1.0-5.64

DCF

0.29

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.5

P/B

-

Website

https://www.allakos.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ALLK News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep